US › Healthcare

Calidi Biotherapeutics Inc. (CLDI)

US · Healthcare · Biotechnology

$1.89+12.50%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-4.1M

Profit YoY

+17.6%

EPS

$-2.21

EPS estimate

$-1.68

EPS came in at -2.21 against a street estimate of -1.68 — a miss of 31.5%.

Key statistics

Market cap

$2.0M

Forward P/E

0.0

P/B

0.40

Book value

$6.62

EPS (TTM)

$-66.72

52-week high

$114.08

52-week low

$1.49

50-day MA

$2.23

200-day MA

$10.57

Beta

1.33

Analyst view

Analysts rate Calidi Biotherapeutics Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $120.00.

Shareholding

Insiders

1.87%

Institutions

10.62%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Calidi Biotherapeutics Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.